ALX Oncology Holdings Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ALX Oncology Holdings Inc. on June 25, 2026. The filing discloses the entry into a new material definitive loan agreement and the termination of a prior loan agreement.
Key Financial Metrics and Debt Structure
The Company entered into a secured multi-tranche term loan facility with HSBC Ventures USA Inc. Key terms include:
- Total Facility Size: Up to $50,000,000 in aggregate principal.
- Initial Draw: $10,000,000 borrowed at closing.
- Available Commitments: $20,000,000 available to draw through June 30, 2028.
- Milestone Tranche: An additional $10,000,000 available upon achieving specific clinical milestones (positive Phase 2 ASPEN-09 data for Evorpacept and positive Phase 1 safety data for ALX2004).
- Discretionary Tranche: Up to $10,000,000 available at the Lender's sole discretion.
- Interest Rate: Floating rate equal to the greater of the Prime Rate or 6.0% per annum.
- Maturity Date: June 1, 2030.
- Amortization: Begins July 1, 2028, or July 1, 2029 if an Interest Only Milestone Event occurs.
- Use of Proceeds: Refinancing existing debt with Oxford Finance and Silicon Valley Bank, paying closing fees, and general corporate purposes.
Material Changes Versus Prior Period
The Company terminated its existing Loan Agreement dated October 27, 2022, with Oxford Finance LLC and Silicon Valley Bank. The proceeds from the new HSBC facility were used to pay off all outstanding principal, interest, and other amounts owing under the prior agreement.
Management Commentary, Risks, and Covenants
The Loan Agreement includes customary affirmative and negative covenants restricting asset dispositions, mergers, additional debt incurrence, liens, dividends, and affiliate transactions. The obligations are secured by substantially all assets of the Borrower and guarantors, with a negative pledge on intellectual property. Events of default include payment defaults, breaches of covenants, and insolvency, which could lead to acceleration of obligations. Prepayment fees apply (2.0% within the first year, 1.0% in the second year), and a 2.00% final payment fee is due upon termination or maturity.
Investor Verification Checklist
- Verify the specific clinical milestones required to unlock the $10,000,000 tranche related to Evorpacept and ALX2004.
- Confirm the exact outstanding balance of the refinanced Oxford Finance and Silicon Valley Bank debt to assess the net cash impact.
- Review the full text of the Loan Agreement (to be filed in the Form 10-Q for the quarter ended June 30, 2026) for detailed covenant definitions and exceptions.
- Monitor the Company's cash burn rate against the $20,000,000 committed availability to assess liquidity runway.